Compare Pfizer Inc (PFE) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Under Armour Inc Class A — how do they compare? Pfizer Inc trades at $24.91 (market cap $142.14B), while Under Armour Inc Class A trades at $7.08 (market cap $3.11B). The key difference: Pfizer Inc is far larger — about 45.7× Under Armour Inc Class A's market cap, and Pfizer Inc pays a 6.9% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| PFE | UA | |
|---|---|---|
Market Cap | $142.14B | $3.11B |
Volume | 29,869,932 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $28.56 | $7.88 |
52-Week Low | $23.29 | $3.96 |
Enterprise Value | $192.80B | $4.74B |
Dividend Yield | 6.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.
PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.
Under Armour (UA) trades at $7.13, down 2.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $201.27 million in fiscal 2025, with negative margins and cash flow, though revenue remains substantial at $5.16 billion. Recent news highlights a new Dodge collaboration and an upcoming Q1 2027 earnings call on August 7, 2026.
Outlook is mixed: analyst consensus leans slightly bullish with 40% buy ratings, but fundamental challenges persist including declining revenue projections and negative profitability. Key risks include execution of the business reset and competitive pressures. The stock presents a turnaround opportunity but requires careful monitoring of earnings and margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
